Combination of All-Trans Retinoic Acid Resumes the Sustained Response of TPO-RA in ITP

The study investigated the effectiveness of combining all-trans retinoic acid (ATRA) with thrombopoietin receptor agonists (TPO-RA) to stabilize platelet counts in idiopathic thrombocytopenic purpura (ITP) patients. Conducted at Nanfang Hospital, the study included 15 patients after excluding 2 due to severe headaches. The results showed that ATRA, administered at 20 mg daily, successfully resumed platelet response in 86.67% of cases. The treatment was generally well-tolerated, with side effects such as dry lips, hair loss, headache, and rash occurring at low rates. The findings suggest that short-term ATRA treatment is both effective and safe for managing platelet fluctuations in ITP patients on TPO-RA therapy.